Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Menlo Therapeutics Inc (MNLO)

Menlo Therapeutics Inc (MNLO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Menlo Therapeutics CEO to Participate in Fireside Chat at the Piper Jaffray 31st Annual Healthcare Conference

Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Steve Basta, chief executive...

MNLO : 5.33 (-2.74%)
FOAMIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Foamix Pharmaceuticals Ltd. - FOMX

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Foamix Pharmaceuticals Ltd. (NasdaqGS: FOMX ) to...

FOMX : 4.10 (-1.44%)
MNLO : 5.33 (-2.74%)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Merger of Menlo Therapeutics Inc. with Foamix Pharmaceuticals Ltd. is Fair to MNLO Shareholders

The following statement is being issued by Levi & Korsinsky, LLP:

MNLO : 5.33 (-2.74%)
FOMX : 4.10 (-1.44%)
SHAREHOLDER ALERT: WeissLaw LLP Investigates Foamix Pharmaceuticals Ltd.

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Foamix Pharmaceuticals Ltd. ("FOMX" or the "Company") (NASDAQ: FOMX) in connection...

FOMX : 4.10 (-1.44%)
MNLO : 5.33 (-2.74%)
Foamix and Menlo Therapeutics to Merge, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications

-- Menlo's serlopitant for pruritus associated with prurigo nodularis ("PN") complements Foamix's existing portfolio and addresses a significant unmet medical need for a serious disease state

MNLO : 5.33 (-2.74%)
Menlo Therapeutics Reports Third Quarter 2019 Financial Results and Provides Program Updates

Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced financial results for the...

MNLO : 5.33 (-2.74%)
Menlo Therapeutics Announces Completion of Enrollment in Two Phase 3 Trials of Serlopitant in Prurigo Nodularis

- Pivotal results expected in March/April 2020 -

MNLO : 5.33 (-2.74%)
Menlo Therapeutics to Host Investor Day October 29, 2019

-Management to Review Late Stage Development, NDA-readiness and Commercial Opportunity of Serlopitant-

MNLO : 5.33 (-2.74%)
Menlo Therapeutics Presents Successful Phase 2 Clinical Trial Results of Serlopitant in Psoriasis at the European Academy of Dermatology and Venereology Meeting

Menlo Therapeutics Inc. (Nasdaq: MNLO), a late-stage biopharmaceutical company, presented results from its successful Phase 2 clinical trial of serlopitant for the treatment of pruritis in patients with...

MNLO : 5.33 (-2.74%)
Menlo Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Steven Basta, chief executive...

MNLO : 5.33 (-2.74%)
Menlo (MNLO) Completes Enrollment in Phase II Pruritus Study

Menlo (MNLO) completes enrollment in the phase II study evaluating the safety and efficacy of once-daily oral serlopitant for the treatment of CPUO.

MRK : 85.72 (-0.30%)
VNDA : 14.11 (-1.26%)
ACOR : 2.28 (+8.57%)
MNLO : 5.33 (-2.74%)
Menlo Therapeutics Announces Completion of Enrollment of 233 Patients in Phase 2 Trial of Serlopitant in Patients with Chronic Pruritus of Unknown Origin

- Results expected in Q1 2020 -

MNLO : 5.33 (-2.74%)
Menlo Therapeutics to Present at the HC Wainwright 21st Annual Global Investment Conference

Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Kristine Ball, chief...

MNLO : 5.33 (-2.74%)
Menlo Therapeutics Reports Second Quarter 2019 Financial Results and Provides Program Updates Including Accelerated Timeline for Upcoming Clinical Data

Results from Serlopitant Phase 2 Clinical Trial for the Treatment of Chronic Pruritus of Unknown Origin Anticipated in Q1 2020

MNLO : 5.33 (-2.74%)
Menlo Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference

Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Steve Basta, Menlo's...

MNLO : 5.33 (-2.74%)
Life Science Company Live Investor Presentations Now Available for On-Demand Viewing

Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the July 11th life sciences conference are now available for on-demand viewing...

LXX.CN : 0.620 (-6.06%)
MNLO : 5.33 (-2.74%)
NGW.CN : 0.125 (-3.85%)
Life Science Company Live Investor Conference July 11th

Life science company executives will share vision and answer audience questions at VirtualInvestorConferences.com

LXX.CN : 0.620 (-6.06%)
MNLO : 5.33 (-2.74%)
NGW.CN : 0.125 (-3.85%)
Menlo Therapeutics to Present at Upcoming Investor Conferences

Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Steve Basta, Chief Executive...

MNLO : 5.33 (-2.74%)
EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Menlo Therapeutics, Inc. of Class Action Lawsuit

The following statement is being issued by Levi & Korsinsky, LLP:

MNLO : 5.33 (-2.74%)
Menlo Therapeutics Reports First Quarter 2019 Financial Results

Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced financial results for the...

MNLO : 5.33 (-2.74%)

Van Meerten Stock Picks

My 5 Favorite Mid Caps
Summary 100% technical buy signals with current momentum.
CRUS -3.17 , SEDG -8.74 , THC -0.37 , TER -2.57 , LITE -2.59
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar